Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. Co.'s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). Co. designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The OMGA average annual return since 2021 is shown above.
The Average Annual Return on the OMGA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OMGA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OMGA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|